Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

被引：2
|
作者：
Zhang, Tongtong [1 ,2 ]
Zhou, Haixia [1 ,2 ]
Xu, Mingzhu [1 ,2 ]
Qian, Chongsheng [1 ,2 ]
Sun, Aining [1 ,2 ]
Wu, Depei [1 ,2 ]
Xue, Shengli [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215000, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou 215000, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2023年 / 102卷 / 04期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1007/s00277-023-05110-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：973 / 975
页数：3
相关论文
共 50 条
  • [41] Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
    Ryan, Christine E.
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    McDonough, Mikaela M.
    Montegaard, Josie S.
    Kim, Austin, I
    Soumerai, Jacob D.
    Alencar, Alvaro J.
    Bhandari, Shruti
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2022, 140 : 9871 - 9872
  • [42] Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Danilov, Alexey V.
    Lam, Vi
    Bria, Thurlow
    Spurgeon, Stephen E.
    Park, Byung
    Orand, Kirsten
    Kittai, Adam S.
    BLOOD, 2021, 138
  • [43] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Hou, Yue
    Hu, Yu
    Li, Weiming
    Liu, Xiaoli
    Xu, Na
    Song, Yongping
    Zhang, Gongli
    Meng, Li
    Hong, Zhenya
    Liu, Bingcheng
    Li, Yan
    Chen, Suning
    Xue, Mengxing
    Zhu, Huanling
    Li, He
    Du, Xin
    Lou, Jin
    Zhang, Xiaohan
    Liang, Yang
    Dai, Yujun
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    BLOOD, 2021, 138
  • [44] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas K.
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [45] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Jurczak, Wojciech
    Elmusharaf, Nagah
    Fox, Christopher P.
    Townsend, William
    Paulovich, Amanda G.
    Sharma, Shringi
    Parr, Graeme
    Munugalavadla, Veerendra
    Krantz, Fanny
    Yang, Helen
    Dean, Emma
    Manwani, Richa
    Hillmen, Peter
    CANCER RESEARCH, 2022, 82 (12)
  • [46] A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML)
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Konopleva, Marina
    Hong, Kyu
    Huang, Tao
    Song, An
    Wieland, Elizabeth
    Woodard, Paul
    Liao, Charlene
    Zhang, Chengcheng
    Patel, Prapti A.
    Aribi, Ahmed
    BLOOD, 2020, 136
  • [47] Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Pemmaraju, Naveen
    Bhalla, Kapil N.
    Daver, Naval
    Wilson, Nathaniel R.
    Fiskus, Warren C.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Burger, Jan A.
    Short, Nicholas J.
    Alvarado, Yesid
    Jain, Nitin
    Masarova, Lucia
    Verstovsek, Srdan
    Issa, Ghayas C.
    Qiao, Wei
    Khoury, Joseph D.
    Pierce, Sherry A.
    Miller, Darla
    Konopleva, Marina
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [48] BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
    Ozcan, Muhit
    Lavie, David
    Chaudhry, Arvind
    Zhou, Xuan
    Paydar, Ima
    Farooqui, Mohammed Z. H.
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 244 - 251
  • [50] Successful induction of hematologic and cytogenetic remission with gemtuzumab ozogamicin (mylotarg(R)) in patients with myeloid blast crisis of chronic myelogenous leukemia in refractory to imatinib mesylate and chemotherapy.
    Weng, JY
    Du, X
    Wu, SJ
    Lu, ZS
    Huang, ZL
    Lin, W
    BLOOD, 2005, 106 (11) : 295B - 295B
12345